Literature DB >> 14630270

Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer.

Jan T W Lim1, Pauline T Truong, Eric Berthelet, Howard Pai, Howard Joe, Elaine Wai, Stephan Larsson, Hosam A Kader, Brian Weinerman, Kenneth Wilson, Ivo A Olivotto.   

Abstract

PURPOSE: To determine the role of endoscopic surveillance in predicting organ preservation and survival after primary chemoradiotherapy (CRT) for esophageal cancer.
MATERIALS AND METHODS: Fifty-six consecutive patients with nonmetastatic esophageal cancer were treated with primary CRT between May 1993 and April 1999 with curative intent and subsequent surveillance with endoscopy and CT scans. Patients with residual disease on endoscopy and/or CT 6 weeks after CRT were considered for immediate esophagectomy. The remaining patients continued endoscopic surveillance and were considered for esophagectomy only when local relapse was detected. Five-year survival was estimated using the Kaplan-Meier method, and univariate and multivariate analyses were performed to identify significant factors associated with disease-specific survival.
RESULTS: With a median follow-up of 62 months, the 5-year overall and disease-specific survival was 30% (95% confidence interval [CI]: 17%-43%) and 37% (95% CI: 22%-50%), respectively. Fourteen of 24 (58%) patients who survived more than 2 years did not require an esophagectomy. On univariate analysis, favorable prognostic factors for disease-specific survival were female gender (p = 0.026), CT-defined N(0) status (p = 0.027), and negative endoscopy at 6 weeks after CRT (p < 0.0001). On multivariate analysis, N(0) status and negative endoscopy after CRT remained significant (p = 0.03 and p < 0.0001, respectively) for disease-specific survival. On multivariate analysis for overall survival, female gender and negative endoscopy were significant (p = 0.35 and p < 0.001, respectively). The hazard ratios for disease-specific survival with positive nodal status and positive endoscopy were 2.44 (95% CI: 1.14-5.3) and 5.18 (95% CI: 2.3-11.6), respectively.
CONCLUSIONS: Endoscopic response after primary CRT for esophageal cancer was the most significant predictive factor for overall and disease-specific survival. Regular endoscopic surveillance after CRT achieved survival rates comparable to other strategies and successfully preserved the esophagus in the majority of patients who survived more than 2 years.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14630270     DOI: 10.1016/s0360-3016(03)00751-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis.

Authors:  Ulrike Heger; Franz Bader; Florian Lordick; Maria Burian; Rupert Langer; Martin Dobritz; Susanne Blank; Thomas Bruckner; Karen Becker; Ken Herrmann; Jörg-Rüdiger Siewert; Katja Ott
Journal:  Gastric Cancer       Date:  2013-09-01       Impact factor: 7.370

Review 2.  Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment.

Authors:  Elfriede Bollschweiler; Arnulf H Hölscher; Matthias Schmidt; Ute Warnecke-Eberz
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

3.  Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.

Authors:  Frederic Di Fiore; Stephane Lecleire; Olivier Rigal; Marie-Pierre Galais; Emmanuel Ben Soussan; Isabelle David; Bernard Paillot; Jacques-Henri Jacob; Pierre Michel
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

4.  Elective nodal irradiation or involved-field irradiation in definitive chemoradiotherapy for esophageal squamous cell cancer: a retrospective analysis in clinical N0 patients.

Authors:  Y Sun; X L Zhang; Q F Mao; Y H Liu; L Kong; M H Li
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

5.  Evaluation of Roles of MicroRNA-21 and MicroRNA-18a in Esophageal Squamous Cell Carcinoma and Comparison of Their Changes in Expression Post-Chemoradiotherapy.

Authors:  Mohd Talha Noor; Nivesh Seehra; Jitendra Rajput; Rajeev Sharma; Bhagwan Singh Thakur
Journal:  Gastroenterology Res       Date:  2020-06-18

6.  Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.

Authors:  Susanne Blank; Florian Lordick; Franz Bader; Maria Burian; Martin Dobritz; Lars Grenacher; Karen Becker; Wilko Weichert; Rupert Langer; Leila Sisic; Annika Stange; Dirk Jäger; Markus Büchler; Thomas Bruckner; Jörg Siewert; Katja Ott
Journal:  Gastric Cancer       Date:  2014-04-11       Impact factor: 7.370

7.  SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus.

Authors:  Christopher N Hurt; Lisette S Nixon; Gareth O Griffiths; Ruby Al-Mokhtar; Simon Gollins; John N Staffurth; Ceri J Phillips; Jane M Blazeby; Tom D Crosby
Journal:  BMC Cancer       Date:  2011-10-28       Impact factor: 4.430

8.  Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas.

Authors:  T Schmidt; L Sicic; S Blank; K Becker; W Weichert; T Bruckner; T Parakonthun; R Langer; M W Büchler; J-R Siewert; F Lordick; K Ott
Journal:  Br J Cancer       Date:  2014-02-25       Impact factor: 7.640

9.  Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome.

Authors:  Antoine Adenis; Emmanuelle Tresch; Sylvain Dewas; Olivier Romano; Mathieu Messager; Eric Amela; Stéphanie Clisant; Andrew Kramar; Christophe Mariette; Xavier Mirabel
Journal:  BMC Cancer       Date:  2013-09-06       Impact factor: 4.430

10.  Immediate tumor resection in patients with locally advanced gastroesophageal adenocarcinoma with nonresponse to chemotherapy after 4 weeks of treatment versus resection after completion of chemotherapy (OPTITREAT trial, DRKS00004668): study protocol for a randomized controlled pilot trial.

Authors:  Susanne Blank; Phillip Knebel; Georg-Martin Haag; Thomas Bruckner; Ulla Klaiber; Maria Burian; Anja Schaible; Leila Sisic; Thomas Schmidt; Markus K Diener; Katja Ott
Journal:  Pilot Feasibility Stud       Date:  2016-04-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.